Targeted immunotherapy added to chemotherapy and radiation for lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests whether adding targeted immunotherapy to standard chemotherapy and radiation can improve outcomes in children with certain types of lymphoma. It may help the immune system work better against cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child or teen with newly diagnosed lymphoma
- Your lymphoma type must be one of these: Burkitt/Burkitt-like, high-grade B-cell, diffuse large B-cell, or classical Hodgkin lymphoma
- Your disease stage or test results must match one of the study groups (for example advanced stage, certain bone marrow or CNS involvement, or higher-risk features)
- Your kidneys, liver, and other organ systems must be functioning well enough for treatment
- You cannot have specific excluded lymphoma types (like primary mediastinal B-cell lymphoma or gray zone lymphoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
This trial tests two new treatment combinations for children and young adults with B-cell non-Hodgkin lymphoma that has come back or not responded to previous therapy. The goal is to find better options for treating this cancer.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.